Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

A glycosylation near antigenic site A in H7 hemagglutinin determines H7 influenza virus sensitivity to neutralizing antibodies

International Conference on Influenza

Esmeralda Alvarado-Facundo, Russell Vassell, Falko Schmeisser, Jerry Weir, Carol D. Weiss and Wei Wang

Center for Biologics Evaluation and Research, US-FDA, USA

Posters-Accepted Abstracts: J Infect Dis Ther

DOI: 10.4172/2332-0877.C1.006

Abstract
Human infections with H7 subtype of influenza virus have been reported, including an A(H7N7) outbreak in Netherlands in 2003 and A(H7N9) infection in China in 2013. We previously isolated three murine monoclonal antibodies (mAbs), 5A6, 4A2 and 2C4 that target the antigenic site A of H7 hemagglutinin (HA). To better understand the efficacy of H7 vaccines and vaccine candidate selection, we used our panel of mAbs to assess antigenic relatedness among H7 hemagglutinins and residues of HA that affect the susceptibility to neutralization. We found that these mAbs neutralized wild type A/Shanghai/02/2013 HA-pseudovirus, but not A/Netherlands/219/2003. Furthermore, the glycosylation of residue aspartic acid at 141 (N141) in A/Netherlands/219/2003 HA is responsible for this resistance. The glycosylation of N141 is due to A143T substitution in A/ Netherlands/219/2003 HA. This mutation of residue 143 also plays an important role in infectivity of the HA-pseudoviruses. The A143 decreases the HA-pseudovirus infectivity. These results demonstrate that residue 143 not only affects H7 sensitivity to neutralizing antibodies, but also viral infectivity.
Biography

Esmeralda Alvarado-Facundo completed her PhD in 2013 from Instituto Politecnico Nacional (Mexico) in collaboration with CBER, US FDA. She is doing postdoctoral studies at CBER-FDA studying influenza virus hemagglutinin and its influence on virus infection, immunogenicity, and susceptibility to neutralizing antibodies.

Email: esmevaccine@gmail.com

Top